Details of the Drug

General Information of Drug (ID: DMBQ6XY)

• Drug Name: TP-3654
• Synonyms: 1361951-15-6; TP3654; UNII-EOB0N7BOY4; EOB0N7BOY4; SGI-9481; 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol; SCHEMBL102560; CHEMBL3975308; SCHEMBL19986953; SCHEMBL20794171; SCHEMBL22421478; BDBM242374; BCP30070; EX-A1828; NSC805149; AKOS032960444; CS-6293; NSC-805149; SB17245; TP3654; TP 3654; BS-15262; HY-101126; AK00792306; S6774; US9416132, 8-31; 2-(4-((3-(3-(Trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino)cyclohexyl)propan-2-ol; 4-((3-(3-(Trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino) -trans-cyclohexyl)propan-2-ol

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 418.5
  Logarithm of the Partition Coefficient (xlogp); 4.6
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 7
• Chemical Identifiers:
  Formula: C22H25F3N4O
  IUPAC Name: 2-[4-[[3-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]cyclohexyl]propan-2-ol
  Canonical SMILES: CC(C)(C1CCC(CC1)NC2=NN3C(=NC=C3C4=CC(=CC=C4)C(F)(F)F)C=C2)O
  InChI: InChI=1S/C22H25F3N4O/c1-21(2,30)15-6-8-17(9-7-15)27-19-10-11-20-26-13-18(29(20)28-19)14-4-3-5-16(12-14)22(23,24)25/h3-5,10-13,15,17,30H,6-9H2,1-2H3,(H,27,28)
  InChIKey: XRNVABDYQLHODA-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 66598080
  CAS Number: 1361951-15-6
  TTD ID: D7Z1CR

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase pim (PIM)	TTA7WGU	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03715504) Study of TP-3654 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.